All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
During the American Society of Clinical Oncology (ASCO) Virtual Meeting 2020, David Sallman from the Moffitt Cancer Center, US, presented an abstract on 5F9005, a phase Ib study (NCT03248479), investigating the safety and efficacy of magrolimab plus azacytidine (AZA) in patients with myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).1 He presented data from the expansion cohort.
Magrolimab (Hu5F9-G4), which was last year granted fast track designation by the U.S Food and Drug Administration, is a first-in-class antibody against CD47, a macrophage immune checkpoint protein. This antibody has been shown to block phagocytic evasion, inducing tumor phagocytosis, which facilitates the elimination of malignant cells. In preclinical models, a synergy of magrolimab with AZA has been observed. The 5F9005 study was designed to examine whether such synergy can be seen in patients, and to assess the tolerability and clinical activity of the combination.
Patients with untreated AML who were ineligible for induction therapy or with untreated intermediate/very high-risk MDS were eligible for the study. The study was designed as a dose escalation (N = 6) followed by cohort expansion. Magrolimab was administered in an escalating dose from (1–30 mg/kg) for the first 2 weeks. Then at a maintenance dose of 30 mg/kg weekly (Q1W) throughout, or once every 2 weeks (Q2W) from Cycle 3+. AZA (75 mg/m2) was given on Day 1–7 of each cycle.
The primary objectives of the study were safety and efficacy assessed by the International Working Group 2006 (MDS), and the European Leukemia Net 2017 (AML) criteria. Secondary objectives included pharmacokinetics, pharmacodynamics, and immunogenicity, while exploratory objectives aimed to assess CD47 receptor occupancy, markers of immune cell activity, and molecular profiling in AML/MDS.
Based on pharmacokinetics, pharmacodynamics, and a similar receptor occupancy with Q1W and Q2W, Q2W dosing was selected.
Baseline patient and disease characteristics are presented in Table 1.
Table 1. Selected baseline patient and disease characteristics in untreated MDS and AML
AML, acute myeloid leukemia; MDS, myelodysplastic syndromes; MRC, myelodysplasia-related changes; NA, not applicable; RS, ringed sideroblasts; WHO, World Health Organization |
|||
Characteristic |
MDS (N = 39) |
AML (N = 29) |
|
---|---|---|---|
Median age (range), years |
70 (47–80) |
74 (60–89) |
|
Cytogenetics risk, % Intermediate Poor Unknown |
28 64 8 |
7 72 21 |
|
WHO AML classification, % MRC Recurrent genetic abnormalities Therapy related Not otherwise specified |
NA |
66 7 10 17 |
|
WHO MDS classification, % RS and single/multi-lineage dysplasia Multi-lineage dysplasia RS with multi-lineage dysplasia Excess blasts Unclassifiable/unknown |
3 18 8 56 15 |
NA |
|
Therapy related MDS, % |
31 |
NA |
|
Harboring TP53 mutation |
13 |
45 |
|
Table 2. Responses with magrolimab plus AZA
AML, acute myeloid leukemia; CR, complete response; CRi, CR with incomplete hematologic recovery; DoR, duration of response; MDS, myelodysplastic syndromes; MRD, measurable residual disease; NA, not applicable; NR, not reached; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease |
||
Best overall response |
MDS (N = 33) |
AML (N = 25) |
---|---|---|
ORR, % |
91 |
64 |
CR, % |
42 |
40 |
CRi, % |
NA |
16 |
PR, % |
3 |
4 |
SD, % |
9 |
32 |
PD, % |
0 |
4 |
MRD negative status, % |
20 |
50 |
Median DoR, months |
NR |
NR |
Median follow-up (range), months |
5.8 (2.0–15.0) |
9.4 (1.9–16.9) |
Table 3. Responses in patients with TP53 mutations
AML, acute myeloid leukemia; CR, complete response; CRi, CR with incomplete hematologic recovery; DoR, duration of response; MRD, measurable residual disease; MDS, myelodysplastic syndromes; NR, not reached |
||
Best overall response |
MDS TP53 mutant |
AML TP53 mutant |
---|---|---|
ORR, % |
75 |
75 |
CR, % |
50 |
42 |
CRi/marrow CR, % |
25 |
33 |
Complete cytogenetic response, n (%) |
3/3 (100) |
4/8 (50) |
MRD negative status of responders, n, (%) |
0 |
4/9 (44) |
Median DoR, months |
NR |
NR |
6-months survival probability, % |
100 |
91 |
Median follow-up (range), months |
7 (4.2–12.2) |
8.8 (1.9–16.9) |
The data indicate that magrolimab, a first-in-class anti-CD47 antibody, in combination with AZA has a manageable toxicity profile and encouraging efficacy in patients with MDS and AML. Moreover, the combination demonstrated activity in patients with TP53 mutations, a high unmet need population with poor outcomes. A further study to explore the efficacy of magrolimab in the TP53 mutated AML is planned.
The cohort expansion study (NCT03248479) in patients with MDS and AML is ongoing, as are the registrational studies for MDS.
Sallman DA, Al Malki M, Asch AS, et al. Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results. Oral abstract #7507. ASCO Annual Meeting 2020; May 29–31, 2020. Virtual.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox